Search results
AstraZeneca Gets Workers’ Covid-19 Faith Bias Suit Narrowed
Bloomberg Law· 12 hours ago‘s bid to dismiss some claims from workers who asserted religious objections to its Covid-19 vaccination mandate proved successful when a federal court adopted a magistrate judge’s recommendations ...
AstraZeneca invests in Nucleus RadioPharmaceuticals - Minneapolis / St. Paul Business Journal
The Business Journals· 9 hours agoAfter completing a $56 million Series A funding round in 2023, Nucleus RadioPharma scored an...
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 2 days agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 2 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
Nucleus RadioPharma secures Series A investment from AstraZeneca
BioPharma-Reporter· 20 hours agoThe investment from AstraZeneca marks a strategic move to further expand Nucleus's capabilities in developing targeted radiotherapies and theranostics, aimed at making cancer ...
AstraZeneca’s Lung, Breast Cancer Drugs Markedly Slow Disease
Bloomberg· 5 days agoAstraZeneca Plc’s lung and breast cancer drugs significantly slowed the spread of disease in two...
AstraZeneca completes Fusion Pharmaceuticals acquisition
Pharmaceutical Technology via Yahoo Finance· 2 days agoAstraZeneca has announced the conclusion of its acquisition of clinical-stage biopharmaceutical...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 21 hours agoFirst Trust Advisors LP grew its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% in the fourth quarter, according to its most recent filing with the Securities ...
Some drugmakers to cap cost of asthma inhalers at $35 a month
NBC News via Yahoo News· 6 days agoStarting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price...
AstraZeneca CEO Has No Plans to Retire as He Seeks to Nearly Double Sales by 2030
The Wall Street Journal· 7 days agoAstraZeneca’s longest-serving chief executive, Pascal Soriot, has no plans to step down for now as...